Before the start of a strike movement launched by several unions in the group, the president of Sanofi France, Audrey Duval, guaranteed Thursday October 17 on RTL the “sustainability” jobs, production sites and Doliprane, while the Opella subsidiary should be sold to an American investment fund.
Asked about the fears of unions regarding the anticipated sale of this entity of non-prescription consumer products, which markets around a hundred brands, including Doliprane, Mme Duval a dit ” to understand [leurs] concerns ». “We hear them (…). It’s normal that they have these questions since, in fact, we are in the middle of an operation which has not been finalized. So the social dialogue and the negotiation process have not started”declared Audrey Duval.
“I guarantee Doliprane in pharmacies for the French”as well as the “sustainability of jobs and sites” of production in France on “several years”she said, while the CFDT and CGT Sanofi unions called on Wednesday for a renewable strike starting Thursday. The unions fear a « social coffers » among the 1,700 jobs Opella has on French soil, including 500 on its Compiègne (Oise) site and 250 in its Lisieux (Calvados) factory, entirely dedicated to Doliprane. The strike will be particularly followed on these two sites, according to the unions.
Read also | Article reserved for our subscribers Sale of Doliprane to an American fund: the government wants guarantees
Add to your selections
The entry of a public actor into the capital of Opella “on the table”
In this possible transaction, the outlines of which are currently being discussed, “Sanofi will remain a 50% shareholder”which gives it a “right of veto over extremely strategic decisions of the group, such as Doliprane”stressed Mme Duval. She insisted that Opella’s headquarters, management team and employees at its French sites ” stay[aient] In France “.
This week, the government asked stakeholders for guarantees in terms of maintaining employment, industrial footprint, location of headquarters and research and development. “Our objective is not to block the sale, it is to obtain written commitments through dialogue. And if we cannot obtain written commitments, we do not prohibit ourselves from using all the other levers”repeated Maud Bregeon, government spokesperson, on Sud Radio on Thursday.
In the opposition, calls to block the sale are becoming urgent. The Landes deputy, Boris Vallaud (Socialist Party), recalled, on Public Senate, that the State had the tools to “enforce” : “The Montebourg decree can be used, can go from establishing conditions to prohibiting the sale. » “If we want to guarantee our sovereignty, there is the possibility of using the Montebourg decree to block the sale”also estimated on Franceinfo the coordinator of La France insoumise, Manuel Bompard.
Read also | Article reserved for our subscribers At Sanofi, behind the sale of the consumer branch, a severe course of restructuring
Add to your selections
Interviewed Tuesday in Les Echos on a possible entry into the capital of a public actor such as the public investment bank Bpifrance, the chairman of the board of directors of Sanofi, Frédéric Oudéa, assured that « all subjects [étaient] on the table ». Bpifrance, “this is not our preference”Audrey Duval said Thursday.
Opella has produced up to 450 million boxes of Doliprane in 2023 for the French market and 20 million euros are currently invested in the Lisieux site to increase production by 140 million boxes per year from 2026. Doliprane is 97% sold in France, a country which only represents around 10% of Opella sales and its second largest market behind the United States. In addition to Doliprane, Opella markets the brands Dulcolax, Lysopaïne, Maalox and Novanuit in France.
